SEC Filings
MACOM Posts $424.8 Million In Sales — And A 31.6% Operating Margin
The semiconductor supplier forecasts another increase in quarterly revenue, while its annual profit comparison includes a refinancing charge.
SEC Filings
The semiconductor supplier forecasts another increase in quarterly revenue, while its annual profit comparison includes a refinancing charge.
SEC Filings
Auryxia sales fell under pressure from generic competition, while inventory reductions limited Vafseo revenue.
SEC Filings
The biotech plans a late-stage abdakibart trial in the first half of 2027; higher operating costs accompanied a narrower quarterly loss.
SEC Filings
Traffic rose 0.8%, but restaurant margins narrowed even as lower food costs helped offset spending on labor and delivery.
SEC Filings
The company plans to use existing cash for the purchase, leaving approximately $493 million of buyback authorization.
SEC Filings
Record orders awaiting delivery support a higher outlook, but data-center growth and production ramp costs squeezed adjusted margins.
SEC Filings
Sales remained 551% above a year earlier, while inventory purchases and investments reduced the drone maker’s cash balance.
SEC Filings
Cemsidomide trial results are expected in 2027, while the company projects enough cash and investments to operate through 2028.
SEC Filings
Lower research costs helped trim the loss as Entrada prepares for four expected clinical readouts through the first half of 2027.
SEC Filings
Free cash flow improved from a year earlier, while Core bought back $84.7 million of stock and added future coal contracts.
SEC Filings
Gen-3 satellite demand drove record intelligence-services sales, while BlackSky kept its capital-spending outlook unchanged.
SEC Filings
The investment manager reported 7,905,757 shares, with sole voting authority covering 7,558,551 shares.